



© Copyright 2012 Oregon State University. All Rights Reserved

Drug Use Research & Management Program  
OHA Division of Medical Assistance Programs  
500 Summer Street NE, E35; Salem, OR 97301-1079  
Phone 503-947-5220 | Fax 503-947-1119



### Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 1, 2024 1:00 - 5:00 PM

Remote Meeting via Zoom Platform

#### MEETING AGENDA

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.**

#### I. CALL TO ORDER

- |         |  |  |
|---------|--|--|
| 1:00 PM | <ul style="list-style-type: none"> <li>A. Roll Call &amp; Introductions</li> <li>B. Conflict of Interest Declaration</li> <li>C. Approval of Agenda and Minutes</li> <li>D. Department &amp; Mental Health Clinical Advisory Group Update</li> </ul> | <ul style="list-style-type: none"> <li>R. Citron (OSU)</li> <li>R. Citron (OSU)</li> <li>R. Citron (OSU)</li> <li>A. Gibler (OHA)</li> </ul> |
|---------|--|--|

- |         |                           |                    |
|---------|---------------------------|--------------------|
| 1:30 PM | II. CONSENT AGENDA TOPICS | S. Ramirez (Chair) |
|---------|---------------------------|--------------------|

- A. Quarterly Utilization Report
- B. Zelsuvmi™ (berdazimer) Abbreviated Drug Review
- C. Oncology Prior Authorization Updates
- D. Orphan Drug Policy Updates
  - 1. Public Comment

|         |                     |
|---------|---------------------|
| 1:35 PM | III. DUR ACTIVITIES |
|---------|---------------------|

- |   |  |
|---|--|
| <ul style="list-style-type: none"> <li>A. ProDUR Report</li> <li>B. RetroDUR Report</li> <li>C. Oregon State Drug Review           <ul style="list-style-type: none"> <li>1. Hepatitis C Care for Primary Care Providers</li> <li>2. Asthma Relief Inhaler Drug Use Evaluation</li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>L. Starkweather (Gainwell)</li> <li>D. Engen (OSU)</li> <li>K. Sentena (OSU)</li> </ul> |
|---|--|

#### IV. PREFERRED DRUG LIST NEW BUSINESS

- |         |   |                 |
|---------|---|-----------------|
| 1:50 PM | <ul style="list-style-type: none"> <li>A. Xolair® (omalizumab) Prior Authorization Update           <ul style="list-style-type: none"> <li>1. Prior Authorization Criteria</li> <li>2. Public Comment</li> <li>3. Discussion and Clinical Recommendations to OHA</li> </ul> </li> </ul> | D. Moretz (OSU) |
|---------|---|-----------------|

- |         |  |  |
|---------|--|--|
| 2:05 PM | <p>B. Non-alcoholic Steatohepatitis (NASH) and Weight Management Drugs for NASH and Cardiovascular Disease</p> <ol style="list-style-type: none"> <li>1. Rezdiffra™ (resmetirom) New Drug Evaluation/Prior Authorization Criteria</li> <li>2. Wegovy® (semaglutide) for Cardiovascular Disease Prior Authorization Update</li> <li>3. Public Comment</li> <li>4. Discussion and Clinical Recommendations to OHA</li> </ol> | <p>S. Fletcher (OSU)<br/>S. Servid (OSU)</p> |
| 2:40 PM | <p>C. Antacids Class Updates and New Drug Evaluation</p> <ol style="list-style-type: none"> <li>1. <i>Helicobacter pylori</i> Class Update</li> <li>2. Proton Pump Inhibitor &amp; H2 Antagonist Class Updates</li> <li>3. Voquezna® (vonoprazin) New Drug Evaluation/Prior Authorization Criteria</li> <li>4. Discussion and Clinical Recommendations to OHA</li> </ol>   | <p>K. Sentena (OSU)<br/>D. Moretz (OSU)</p>  |
| 3:10 PM | BREAK  |  |
| 3:25 PM | <p>D. Targeted Immune Modulators DERP Summary</p> <ol style="list-style-type: none"> <li>1. Ulcerative Colitis/Crohn's Disease DERP Report</li> <li>2. Psoriasis/Psoriatic Arthritis DERP Report</li> <li>3. Prior Authorization Criteria</li> <li>4. Public Comment</li> <li>5. Discussion and Clinical Recommendations to OHA</li> </ol>   | <p>D. Moretz (OSU)</p>                       |
| 3:55 PM | V. EXECUTIVE SESSION   |  |
| 4:50 PM | VI. RECONVENE for PUBLIC RECOMMENDATIONS   |  |
|         | VII. ADJOURN   |  |